Case Study Overview
This case study examines an integrated live‑cell imaging assay used to characterize antibody‑drug conjugate (ADC) mechanisms within 3D tumor–immune co‑cultures. By capturing real‑time payload‑driven, immune‑mediated, and bystander killing dynamics in a single experimental system, the approach provides a mechanistic resolution not achievable with traditional endpoint assays.
Comparative analysis of Kadcyla and Enhertu highlights distinct target‑restricted and bystander effects, reflecting clinically observed behaviors. The dataset demonstrates how kinetic and population‑level measurements in complex models can improve early ADC evaluation and support more informed therapeutic selection.
Resource Details:
- Document Type: Case Study
- Page Count: 7 pages
- Read Time: 8 minutes
Key Takeaways
- The integrated assay let researchers watch ADC effects unfold in real time, revealing differences that standard endpoint assays often miss.
- Kadcyla and Enhertu showed clearly distinct behaviors, from target‑restricted killing to meaningful bystander effects.
- Seeing payload, immune, and bystander activity together in one system gives teams a clearer picture of how ADCs actually perform in complex tumor environments.
Audience & Applications:
- Biopharma scientists and researchers working in ADC discovery, preclinical development, and bioassay design.
- Drug development and translational research teams evaluating ADC mechanisms, cytotoxicity, and tumor–immune interactions.
- Bioanalytical and mechanistic pharmacology specialists who rely on advanced in vitro models and live‑cell imaging.
